RedChip's  Instablog

Send Message
RedChip's long history of success includes the first to issue independent research coverage on Starbucks in 1992. Other names RedChip discovered as they were on the cusp of becoming Blue-Chip stocks were: Nike™,™, Daktronics™. Over the years, RedChip has evolved into a... More
My company:
RedChip Companies, Inc.
My blog:
Smallcap Ideas
  • Stem Cell Therapies Set To Revolutionize Disease Treatment 1 comment
    Dec 21, 2012 9:02 AM | about stocks: EBIG

    The 2012 Nobel Prize in Physiology and Medicine was awarded to Shinya Yamanaka of Kyoto University in Japan and John Gurdon of the University of Cambridge in England. Dr. Yamanaka and Dr. Gurdon received the award "for the discovery that mature cells can be reprogrammed to become pluripotent," an important step in the widespread commercialization of stem cell therapies.

    While many stem cell therapies are still in experimental stages, or too costly for mass adoption, ongoing advances in the space are prevalent. It's becoming widely accepted amongst medical researchers that stem cell therapies will soon be able to treat cancer, diabetes, neurological disorders, muscle damage, Parkinson's, cardiac failure, and many other diseases.

    One company with a first-mover advantage in China's stem cell market is Cellular Biomedicine Group ("CBMG"). CBMG has successfully acquired, transferred, commercialized and advanced 30 years of research and human treatment experience in progenitor cells and cancer cell technology. The Company's cellular research and development is the result of collaboration between scientists and doctors from both the U.S. and China.

    CBMG announced on Nov. 14, 2012 that it entered into an agreement to merge with EastBridge Investment Group Corp. (OTCQB: EBIG), a financial consulting firm focused on providing professional advice to small, high-growth companies seeking to access the U.S. capital markets. The merger is anticipated to complete in January 2013. The combined entity will operate in two segments, with EastBridge continuing its current operational focus as a division of the parent company.

    CBMG scientists currently develop biomedicine based on tissue-derived progenitor (stem) cells, embryonic stem cells (NYSE:ES), cytokine induced killer cells (NYSEMKT:CIK) and cancer-specific dendritic cells. The Company considers these types of cells as viable options for cell-based therapies that can be applied to a variety of medical indications. Ongoing research will determine the most effective applications for each type of cell.

    The Company's technologies are founded on scientific innovations in the field of regenerative medicine. CBMG's IP portfolio of cellular biomedicine products target cancer, osteoarthritis, tissue damage as a result of stroke, spinal muscular atrophy, various inflammatory diseases, joint repair, metabolic diseases and ophthalmology diseases.

    Investors have a lot of upside with CBMG. It has the right management and scientific team in place to move its robust product pipeline through to commercialization. As an added bonus, once the merger with EBIG is complete in January, the Company will have additional high-margin revenue generation from EBIG's core financial consulting business. This added cash flow will further support the Company's product development efforts.

    To learn more about this exciting opportunity with China's stem cell leader, view CBMG's recent presentation from our December virtual conference or contact a specialist today at 1-407-644-4256, ext. 0.

    Disclosure: The subject security is a client of RedChip Companies, Inc. RedChip Companies, Inc., employees and affiliates may have positions and affect transactions in the securities or options of the issuers mentioned herein. For full financial disclosures for all RedChip clients, please visit

    Stocks: EBIG
Back To RedChip's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (1)
Track new comments
  • silence_twain
    , contributor
    Comments (338) | Send Message
    Any comment on the Longwei fraud article that came out today? I saw the following press release about you guys working with them last week.


    TAIYUAN CITY, China, Dec. 28, 2012 /PRNewswire-Asia/ -- Longwei Petroleum Investment Holding Ltd. (NYSE MKT: LPH) ("Longwei" or the "Company"), an energy company engaged in the storage and distribution of finished petroleum products in the People's Republic of China ("PRC"), has renewed its agreement with RedChip Companies, Inc. ("RedChip") for investor relations services.


    "We've had the pleasure of working with RedChip for more than four years," said Cai Yongjun, Chairman and Chief Executive Officer of Longwei. "They have been with us since our initial entrance into the U.S. capital markets and have played a key role in our investor communication efforts. We are pleased to continue our relationship with RedChip as we enter yet another high-growth phase of our business."


    "RedChip's platform has served us well over the past four years," stated Michael Toups, Chief Financial Officer of Longwei. "More recently, we've benefited from added exposure of our story through RedChip's new television program, 'The RedChip Money Report.' We plan to use multiple platforms to continue to disseminate the Company's story to both institutional and retail investors."


    Dave Gentry, President and CEO of RedChip, stated, "With strong leadership at the helm, Longwei has grown from one facility to three since first engaging RedChip. Over the past three years, they have recorded annual sales growth of 45%, with net income rising 28% annually, earning the distinction of Forbes Asia's "Best Under A Billion" in July 2012. We believe Longwei will continue its track record of strong growth in the quarters ahead, capitalizing on the ramp-up of its Huajie facility and organic growth at the Company's two existing facilities.


    "Moving forward, we will leverage the strong capital market foundation we've helped Longwei build over the past four years," continued Mr. Gentry. "We believe our comprehensive investor communication solutions can provide the ideal platform to produce improved valuation metrics for Longwei in the months and quarters ahead."
    3 Jan 2013, 02:23 PM Reply Like
Full index of posts »
Latest Followers


More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.